Sanofi secures exclusive rights to develop plozasiran in Greater China, enhancing treatment options for hypertriglyceridemia ...

A rrowhead Pharmaceuticals’ subsidiary Visirna Therapeutics has entered an asset purchase agreement with Sanofi for the ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the signing of an asset purchase agreement between Sanofi and Visirna Therapeutics, a majority-owned subsidiary of Arrowhead created to ...

Sanofi is handing over $130 million upfront for the China rights to Arrowhead Pharmaceuticals’ rare metabolic disease ...

Arrowhead Pharmaceuticals strikes a $130M+ deal with Sanofi for plozasiran in Greater China, targeting high triglyceride ...

We recently compiled a list of 11 Best Future Stocks to Buy Now. Arrowhead Pharmaceuticals, Inc. stands seventh on our list.

Plozasiran, previously called ARO-APOC3, is a first-in-class investigational RNA interference (RNAi) therapeutic designed to reduce production of Apolipoprotein C-III (APOC3) which is a component ...

Plozasiran is not yet approved for commercial use in the U.S., but, as Healio previously reported, it received a breakthrough therapy designation from the FDA, and Arrowhead plans to file an ...

In patients with severe hypertriglyceridemia, plozasiran, a novel RNA interference agent, lowered apolipoprotein C-III and triglycerides and improved other lipid parameters, according to the final ...

Plozasiran is an investigational RNA interference therapeutic that targets the apolipoprotein C-III (ApoC-III) protein, which inhibits the liver's ability to clear triglycerides out of the body.

- Plozasiran reduced triglycerides and APOC3 up to a mean maximum of 86% and 90% respectively in patients with severe hypertriglyceridemia - SHASTA-3 and SHASTA-4 Phase 3 studies to be initiated ...

Cardiology > Dyslipidemia Plozasiran Paves RNA Interference Path to Triglyceride Reduction — Clinical outcomes pending for people with elevated LDL cholesterol and triglycerides by Nicole Lou ...